Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #1 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited (this stock) | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 15,300 | 4,099 | 2,901 | ₹ |
| March 31, 2026 | 14,612 | 3,551 | 2,710 | ₹ |
| Dec. 31, 2025 | 15,521 | 4,227 | 3,381 | ₹ |
| Sept. 30, 2025 | 14,478 | 4,168 | 3,125 | ₹ |
| June 30, 2025 | 13,851 | 3,173 | 2,293 | ₹ |
| March 31, 2025 | 12,959 | 3,254 | 2,154 | ₹ |
| Dec. 31, 2024 | 13,675 | 3,476 | 2,913 | ₹ |
| Sept. 30, 2024 | 13,291 | 3,598 | 3,037 | ₹ |
| June 30, 2024 | 12,653 | 3,424 | 2,861 | ₹ |
| March 31, 2024 | 11,983 | 2,816 | 2,659 | ₹ |
| Dec. 31, 2023 | 12,381 | 3,000 | 2,561 | ₹ |
| Sept. 30, 2023 | 12,192 | 2,791 | 2,385 | ₹ |
| June 30, 2023 | 11,941 | 2,481 | 2,006 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 58,462 | 15,119 | 11,509 |
| March 31, 2025 | 52,578 | 13,752 | 10,965 |
| March 31, 2024 | 48,497 | 11,088 | 9,610 |
| March 31, 2023 | 43,886 | 9,408 | 8,513 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 12,419 | -11,344 | -2,513 | 3,609 | 8,810 |
| March 31, 2025 | 14,072 | -5,306 | -7,906 | 2,129 | 11,944 |
| March 31, 2024 | 12,135 | -690 | -6,710 | 2,202 | 9,933 |
| March 31, 2023 | 4,959 | -7,944 | 2,376 | 2,086 | 2,874 |
| March 31, 2022 | 8,985 | -5,725 | -5,193 | 1,495 | 7,490 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 108,785 | 83,880 | 83,330 | 4,050 | 31 | 63,860 | 22,622 | 9,771 | 11,114 | 11,493 |
| March 31, 2025 | 92,101 | 72,486 | 71,978 | 1,867 | 3 | 52,594 | 18,194 | 10,269 | 10,036 | 10,243 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
